Logo

Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrop… read more

Healthcare

Biotechnology

7 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$49.78

Price

+1.21%

$0.59

Market Cap

$5.966b

Mid

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-25.0%

5y CAGR
Earnings

-$408.726m

-8.1%

1y CAGR

-36.7%

3y CAGR

-33.4%

5y CAGR
EPS

-$3.45

-4.9%

1y CAGR

-20.7%

3y CAGR

-13.1%

5y CAGR
Book Value

$276.013m

$535.254m

Assets

$259.241m

Liabilities

$205.674m

Debt
Debt to Assets

38.4%

-0.5x

Debt to EBITDA
Free Cash Flow

-$303.860m

-1.1%

1y CAGR

-29.7%

3y CAGR

-24.4%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases